Insider Trading April 17, 2026 04:55 PM

Exzeo CEO Paresh Patel Acquires $33,520 in Company Stock; Holds Multi‑Million Share Option

Executive purchase coincides with a recent weekly gain for XZO and follows quarterly results that met expectations

By Maya Rios XZO
Exzeo CEO Paresh Patel Acquires $33,520 in Company Stock; Holds Multi‑Million Share Option
XZO

Exzeo Group Chief Executive Officer Paresh Patel purchased 2,000 shares on April 16, 2026, at $16.76 per share, a transaction totaling $33,520. The move comes as the company's stock has risen to $17.50, reflecting a 10.42% gain over the prior week. Patel now directly owns 1,616,013 shares and holds an option on 5,000,000 additional shares with a vesting schedule that began in 2021. The company recently reported fourth-quarter and full-year 2025 results that matched analyst forecasts, posting diluted EPS of $0.25 and quarterly revenue of $53.32 million.

Key Points

  • CEO Paresh Patel bought 2,000 shares at $16.76 on April 16, 2026, totaling $33,520.
  • Following the purchase, Patel directly owns 1,616,013 shares and holds an option to buy 5,000,000 shares with a vesting schedule that began in October 2021.
  • Exzeo’s latest financials for Q4 and full-year 2025 matched analyst expectations, reporting diluted EPS of $0.25 and quarterly revenue of $53.32 million; the stock has risen 10.42% over the past week.

Exzeo Group, Inc. disclosed a purchase by Chief Executive Officer Paresh Patel of 2,000 shares of common stock on April 16, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were acquired at $16.76 each, bringing the total consideration for the trade to $33,520.

The transaction coincides with a short-term uptick in the company’s share price. XZO closed at $17.50 in recent trading, a level that represents a 10.42% increase over the preceding week. Publicly reported valuation metrics show a price-to-earnings ratio of 16.13 for the company and a price/earnings-to-growth ratio of 0.16.

After the April 16 purchase, Patel’s direct holdings in Exzeo total 1,616,013 shares. In addition to those shares, Patel is the holder of an option to purchase 5,000,000 shares of common stock. That option is exercisable from October 1, 2021, and its vesting schedule was structured so that one fourth of the option vested on October 1, 2022, with subsequent vesting occurring in one sixteenth increments on each January 1, April 1, July 1 and October 1 thereafter, as detailed in the filing.

Investors and market watchers have also received recent financial disclosures from Exzeo. The company reported fourth-quarter and full-year 2025 results that met consensus expectations. Reported diluted earnings per share for the period were $0.25, in line with analyst forecasts, while quarterly revenue came in at $53.32 million. The report was characterized as demonstrating steady performance over the reported period.

Market commentary included in the filing notes that valuation measures and recent share movement have attracted attention. The stated P/E of 16.13 and a PEG ratio of 0.16 were presented alongside the recent share-price appreciation. The filing also references analysis available through InvestingPro, which includes Fair Value estimates and Pro Research Reports for US equities, noting that additional research resources and ProTips are available to subscribers.

Analyst reaction to the earnings release was acknowledged but not specified. The filing indicated that some analyst firms have adjusted their outlooks in response to Exzeo’s financials, although no individual firms or the substance of those adjustments were named. The company’s financial statements and the insider transaction are part of ongoing disclosures that investors are monitoring for indications of the firm’s direction and financial health.

All transaction details, ownership figures and the option vesting schedule above are taken from the company’s SEC filing and the reported financial statements; no further commentary or forecasting on future performance was provided in the filing.


Context

This filing documents a direct purchase by the CEO, the existing significant equity stake and a large outstanding option grant with a multi-year vesting schedule. The company’s latest quarterly results met prevailing analyst expectations and showed quarterly revenue of $53.32 million alongside diluted EPS of $0.25.

Risks

  • Short-term share-price volatility - XZO rose 10.42% over the past week, indicating recent price movement that may continue.
  • Uncertainty tied to a sizeable option grant - the option to purchase 5,000,000 shares has a multi-step vesting schedule that could affect future insider actions and ownership dynamics.
  • Limited detail on analyst responses - while some firms reportedly adjusted their outlooks after the earnings release, the filing did not specify which analysts or the nature of the revisions, leaving investors with incomplete information on market reactions.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026